Holen Sie sich die Stockscreener-App
29.73
0.87%
-0.26
Schlusskurs vom Vortag:
$29.99
Offen:
$29.78
24-Stunden-Volumen:
242.43K
Relative Volume:
0.70
Marktkapitalisierung:
$492.64M
Einnahmen:
$99.61M
Nettoeinkommen (Verlust:
$-153.60M
KGV:
-1.8075
EPS:
-16.4479
Netto-Cashflow:
$-152.14M
1W Leistung:
-2.30%
1M Leistung:
+13.95%
6M Leistung:
+143.09%
1J Leistung:
+263.54%
1-Tages-Spanne:
$27.80
$30.13
1-Wochen-Bereich:
$27.80
$33.35
52-Wochen-Spanne:
$7.15
$43.85
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
29.73 | 492.64M | 99.61M | -153.60M | -152.14M | -16.45 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-07 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-24 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2026-03-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-20 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-05-08 | Eingeleitet | BofA Securities | Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-06 | Eingeleitet | Oppenheimer | Outperform |
| 2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-10-07 | Eingeleitet | BTIG Research | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Sutro Biopharma (STRO) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Sutro Biopharma (STRO) 2024 Wells Fargo Healthcare Conference Summary - Quartr
Enterprise value to EBITDA forward of Sutro Biopharma, Inc. – NASDAQ:STRO - TradingView
Price to sales forward of Sutro Biopharma, Inc. – NASDAQ:STRO - TradingView
Price to book forward of Sutro Biopharma, Inc. – NASDAQ:STRO - TradingView
Sutro Biopharma (STRO) price target increased by 13.85% to 37.74 - MSN
Sutro Biopharma, Inc.(NasdaqGM:STRO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2500 Growth Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Index - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Value Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Growth Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 3000E Index - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 3000E Value Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2500 Index - marketscreener.com
Sutro Biopharma, Inc. Actuals & Estimates (LSX:A41VMF) - TradingView
Sutro Biopharma, Inc. Actuals & Estimates (NASDAQ:STRO) - TradingView
Sutro Biopharma, Inc. Actuals & Estimates (FWB:S090) - TradingView
STRO Forecast — Price Target — Prediction for 2027 - TradingView
S090 Forecast — Price Target — Prediction for 2027 - TradingView
Sutro Biopharma, Inc. Actuals & Estimates (GETTEX:S090) - TradingView
Sutro Biopharma Inc (STRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sutro Biopharma CSO Hans-Peter Gerber to join 2026 BIO International Convention panel - Traders Union
Barclays Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Sutro Biopharma Inc (STRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sutro Biopharma Inc (STRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sutro Biopharma Inc (STRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sutro Biopharma Inc (STRO) Institutional Confidence - TradingKey
Sutro Biopharma Inc (STRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sutro Biopharma Inc (STRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sutro Biopharma Inc (STRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sutro Biopharma Inc (STRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
This drug 'gave our daughter another chance' — now a nonprofit's deal hopes to secure its use for years to come - The Business Journals
Sutro Biopharma (STRO) Surges Over 9% as Buyers Test Key Resistance at $30.54Elliott Wave Entry - newsline.com
Sutro Biopharma Price Target Announced at $50.00/Share by Truist Securities - Moomoo
Truist Financial Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50 - Moomoo
Sutro Biopharma (STRO) Proxy filing Summary - Quartr
Sutro Biopharma (STRO) director receives 10,000 stock options at $26.09 - Stock Titan
Sutro Biopharma (STRO) director granted 10,000 stock options at $26.09 - Stock Titan
Sutro Biopharma (STRO) director awarded 10,000 stock options at $26.09 strike - Stock Titan
Sutro Biopharma (STRO) director receives 10,000 options vesting into 2027 - Stock Titan
Sutro Biopharma (STRO) director receives 10,000-share stock option grant - Stock Titan
[Form 4] SUTRO BIOPHARMA, INC. Insider Trading Activity - Stock Titan
Sutro Biopharma (STRO) director receives grant of 10,000 stock options - Stock Titan
Director at Sutro Biopharma (STRO) receives 10,000 stock options as equity grant - Stock Titan
Sutro Biopharma (NASDAQ: STRO) reports 2026 annual meeting results - Stock Titan
Sutro Biopharma Surges 5.52% – Testing Key Resistance at $30.11 After Strong SessionAdvance Decline Volume - newsline.com
Sutro Biopharma (STRO) CFO exercises 2,500 RSUs and increases direct holdings - Stock Titan
STRO Q1 2026 Earnings: Narrower Loss Beats Estimates as Sutro Biopharma Advances PipelineTech Earnings Analysis - The Legal Advocate
Barclays Initiates a Buy Rating on Sutro Biopharma (STRO) - The Globe and Mail
STRO Initiated Coverage by Barclays -- Rating Set to Overweight - GuruFocus
Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target - marketscreener.com
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sutro Biopharma Inc-Aktie (STRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 04 '26 |
Option Exercise |
0.00 |
675 |
0 |
10,025 |
| Chung Jane | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
788 |
0 |
21,567 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 02 '26 |
Option Exercise |
0.00 |
2,356 |
0 |
10,320 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):